Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
Launched by UNIVERSITY OF CHICAGO · Jan 17, 2025
Trial Information
Current as of November 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how nutrition and exercise can help adults with a specific type of leukemia called Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) while they are hospitalized for treatment. The goal is to see if improving diet and adding physical activity can have a positive impact on their muscle health and body fat during their chemotherapy treatment.
To participate, individuals must be newly diagnosed with Philadelphia Chromosome Negative B-ALL and receiving intensive chemotherapy. Unfortunately, those who are underweight, pregnant, or unable to follow the diet and exercise guidelines set by the research team cannot join. Participants in this study will wear a device (like a FitBit) to track their activity levels and will take part in both a nutrition plan and an exercise program to see how these changes can benefit their health during treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • New Diagnosis of Philadelphia Chromosome Negative B-ALL
- • Receiving intensive pediatric-inspired induction chemotherapy
- Exclusion Criteria:
- • BMI ≤18.5 kg/m2 at time of diagnosis
- • Unable to comply with both the recommended diet and exercise regimen as deemed by the research or treatment team
- • Pregnant
About University Of Chicago
The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Wendy Stock
Principal Investigator
University of Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported